BACKGROUND: Left atrial appendage emptying flow velocity (LAAEV) depends largely on left atrioventricular compliance and may play a role in mediating the perpetuation of atrial fibrillation (AF) and AF-related outcomes. METHODS: We identified 3,251 consecutive patients with sustained AF undergoing first-time successful transesophageal echocardiography (TEE)-guided electrical cardioversion who were enrolled in a prospective registry between May 2000 and March 2012. Left atrial appendage emptying flow velocity was stratified into quartiles: ≤20.2, 20.3-33.9, 34-49.9, and ≥50 cm/s. Multivariate Cox regression models were used to identify independent predictors of AF recurrence, ischemic stroke, and all-cause mortality. RESULTS: The mean (SD) age was 69 (12.6) years and 67% were men. Compared with the fourth quartile, patients in the first-third quartiles were significantly older, had higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack [TIA], vascular disease, age 65-74 years, sex category) scores, greater frequency of atrial spontaneous echo contrast, and AF of longer duration. Kaplan-Meier analysis showed a decreased probability of event-free survival with decreasing quartiles of LAAEV. Five-year cumulative event rates across first-fourth quartiles were 83%, 80%, 73%, and 73% (P < .001) for first AF recurrence; 7.5%, 7.0%, 4.1%, and 4.0%, for stroke (P = .01); and 31.3%, 26.1%, 24.1%, and 19.4%, for mortality (P < .001), respectively. Multivariate Cox regression analysis revealed an independent association of the first and second quartiles with AF recurrence (P < .001 and P < .001, respectively) and stroke (P = .03, and P = .04, respectively), and of the first quartile with mortality (P = .003). CONCLUSIONS: Patients with decreased LAAEV have an increased risk of AF recurrence, stroke, and mortality after successful electrical cardioversion. Real-time measurement of LAAEV by TEE may be a useful physiologic biomarker for individualizing treatment decisions in patients with AF.
BACKGROUND: Left atrial appendage emptying flow velocity (LAAEV) depends largely on left atrioventricular compliance and may play a role in mediating the perpetuation of atrial fibrillation (AF) and AF-related outcomes. METHODS: We identified 3,251 consecutive patients with sustained AF undergoing first-time successful transesophageal echocardiography (TEE)-guided electrical cardioversion who were enrolled in a prospective registry between May 2000 and March 2012. Left atrial appendage emptying flow velocity was stratified into quartiles: ≤20.2, 20.3-33.9, 34-49.9, and ≥50 cm/s. Multivariate Cox regression models were used to identify independent predictors of AF recurrence, ischemic stroke, and all-cause mortality. RESULTS: The mean (SD) age was 69 (12.6) years and 67% were men. Compared with the fourth quartile, patients in the first-third quartiles were significantly older, had higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack [TIA], vascular disease, age 65-74 years, sex category) scores, greater frequency of atrial spontaneous echo contrast, and AF of longer duration. Kaplan-Meier analysis showed a decreased probability of event-free survival with decreasing quartiles of LAAEV. Five-year cumulative event rates across first-fourth quartiles were 83%, 80%, 73%, and 73% (P < .001) for first AF recurrence; 7.5%, 7.0%, 4.1%, and 4.0%, for stroke (P = .01); and 31.3%, 26.1%, 24.1%, and 19.4%, for mortality (P < .001), respectively. Multivariate Cox regression analysis revealed an independent association of the first and second quartiles with AF recurrence (P < .001 and P < .001, respectively) and stroke (P = .03, and P = .04, respectively), and of the first quartile with mortality (P = .003). CONCLUSIONS:Patients with decreased LAAEV have an increased risk of AF recurrence, stroke, and mortality after successful electrical cardioversion. Real-time measurement of LAAEV by TEE may be a useful physiologic biomarker for individualizing treatment decisions in patients with AF.
Authors: Sri Harsha Patlolla; Hon-Chi Lee; Peter A Noseworthy; Waldemar E Wysokinski; David O Hodge; Eddie L Greene; Bernard J Gersh; Rowlens M Melduni Journal: Am J Cardiol Date: 2020-06-30 Impact factor: 2.778
Authors: Tapio Hellman; Tuomas Kiviniemi; Ilpo Nuotio; Fausto Biancari; Tuija Vasankari; Juha Hartikainen; Mika Lehto; K E Airaksinen Journal: Clin Cardiol Date: 2018-07-23 Impact factor: 2.882
Authors: Rowlens M Melduni; Bernard J Gersh; Waldemar E Wysokinski; Naser M Ammash; Paul A Friedman; David O Hodge; Krishnaswamy Chandrasekaran; Jae K Oh; Hon-Chi Lee Journal: Am J Cardiol Date: 2018-03-13 Impact factor: 2.778
Authors: Tapio Hellman; Tuomas Kiviniemi; Tuija Vasankari; Ilpo Nuotio; Fausto Biancari; Aissa Bah; Juha Hartikainen; Marianne Mäkäräinen; K E Juhani Airaksinen Journal: BMC Cardiovasc Disord Date: 2017-01-18 Impact factor: 2.298
Authors: Paweł Wałek; Janusz Sielski; Iwona Gorczyca; Joanna Roskal-Wałek; Katarzyna Starzyk; Elżbieta Jaskulska-Niedziela; Radosław Bartkowiak; Beata Wożakowska-Kapłon Journal: PLoS One Date: 2020-01-29 Impact factor: 3.240
Authors: Rowlens M Melduni; Waldemar E Wysokinski; Zhenzhen Wang; Bernard J Gersh; Samuel J Asirvatham; Sri Harsha Patlolla; Eddie L Greene; Jae K Oh; Hon-Chi Lee Journal: Open Heart Date: 2020-04-06